Compare PLXS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | DNTH |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | 1995 | 2018 |
| Metric | PLXS | DNTH |
|---|---|---|
| Price | $270.27 | $88.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $304.60 | $140.80 |
| AVG Volume (30 Days) | 150.8K | ★ 660.0K |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.11 | N/A |
| EPS | ★ 4.90 | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $14.96 | N/A |
| P/E Ratio | $53.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $132.03 | $32.28 |
| 52 Week High | $307.06 | $117.88 |
| Indicator | PLXS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 35.61 |
| Support Level | $234.17 | $89.21 |
| Resistance Level | $297.13 | $91.04 |
| Average True Range (ATR) | 6.33 | 4.60 |
| MACD | 1.79 | -1.13 |
| Stochastic Oscillator | 75.43 | 23.83 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.